The patient samples from (b)(6) 2017 and (b)(6) 2017 were submitted for investigation.The samples were tested using various methods: elecsys cmv igg, elecsys cmv igg avidity, recomline cmv igg, elecsys toxo igg, an in-house neutralization assay, elecsys toxo igg avidity and recomline toxo igg.The results using the various methods were reproducible.The (b)(6) 2017 sample showed clear reactivity using the elecsys cmv igg assay.The detected antibodies were of high avidity and reactivity.This suggests that cmv directed antibodies were present in the sample.This is additionally supported by the recomline cmv assay results.The sample from (b)(6) 2017 was confirmed to be non-reactive for all cmv assays.Based on investigations performed, the cmv igg and toxo igg results for both samples are considered to be correct.The reactivity pattern of the samples over the course of 6 days does not correspond to a humoral immune response.A specific root cause was not identified.Possible root causes may be related to sample contamination or a sample mix-up.Both reagents perform within specification.
|